Arlington Capital Partners, a Washington, DC-based private equity firm, completed the investment in Everest Clinical Research, a contract research organization. Financial terms were not disclosed. "We are excited to embark upon this new partnership with the impressive Everest team. Everest has built an exceptional organization predicated on continuous innovation, technical excellence, and unwavering quality and customer support. Everest’s expertise in biostatistics and clinical data management together with the Company’s extensive track record of supporting many of the world’s most successful pharmaceutical companies across a diverse array of therapeutic areas and clinical phases provides a strong platform for further growth," Malcolm Little, Arlington Partner.